A new antisickling agent: in vitro studies of its effect on S/S erythrocytes and on hemoglobin S.
2-(benzoylamino) pyridinium benzoate (BAPB) has exhibited an antisickling effect with homozygous S/S erythrocytes in vitro. This study suggests that BAPB prevents sickling by inhibiting the gelation of hemoglobin S.
D000293:Adolescent; D000328:Adult; D000986:Antisickling Agents; D004913:Erythrocytes, Abnormal / Q000187:drug effects; D005260:Female; D006451:Hemoglobin, Sickle; D006801:Humans; D008297:Male; D008875:Middle Aged; D011726:Pyridinium Compounds / Q000494:pharmacology*
D000986:Antisickling Agents; D006451:Hemoglobin, Sickle; D011726:Pyridinium Compounds